What is the Transparency Council going to do on April 4?
AOTMiT: What drugs and health policy programs will be assessed by the Transparency Council?
Published April 1, 2022 08:15
Źródło: AOTMiT
The agenda is:
Preparation of positions on drug evaluation:
Buccolam (midazolamum) in the indication: treatment of prolonged acute seizures in infants, toddlers, children and adolescents (3 months to 18 years),
Jorveza (budesonidum) in the indication: treatment of eosinophilic oesophagitis,
Tecentriq (atezolizumabum) under the drug program: "Treatment of breast cancer with atezolizumab (ICD-10: C50)".
Preparation of a position on the validity of granting consent for the reimbursement of Corgard (nadolol) in the indications: long QT syndrome, polymorphic ventricular tachycardia, arterial hypertension, ventricular arrhythmias, Andersen-Tawil syndrome.
Preparation of an opinion on changes to the drug program: B.75 "Treatment of active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) (ICD-10 M31.3, M31.8)".
Preparation of opinions on draft health policy programs of local government units:
"Program of health policy in the field of therapeutic rehabilitation of the commune of Lubiszyn for the years 2022-2026",
"Treatment of infertility by in vitro fertilization method for the inhabitants of Pyskowice in the years 2022-2025".
Source: AOTMiT
